CJC-1008 in Phase II pain study

ConjuChem (TSE:CJC) began a double-blind, placebo-controlled Phase II trial of its CJC-1008 opioid receptor agonist in 50 patients undergoing total knee replacement surgery. The primary endpoint is co...